Free Trial
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics logo
$12.96 -0.12 (-0.93%)
As of 09:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About 10x Genomics Stock (NASDAQ:TXG)

Key Stats

Today's Range
$12.81
$13.11
50-Day Range
$8.17
$14.64
52-Week Range
$6.78
$24.76
Volume
167,506 shs
Average Volume
3.41 million shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.23
Consensus Rating
Hold

Company Overview

10x Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

TXG MarketRank™: 

10x Genomics scored higher than 78% of companies evaluated by MarketBeat, and ranked 203rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 6 buy ratings, 5 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    10x Genomics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 10x Genomics' stock forecast and price target.
  • Earnings Growth

    Earnings for 10x Genomics are expected to grow in the coming year, from ($1.43) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 10x Genomics is -10.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 10x Genomics is -10.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    10x Genomics has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about 10x Genomics' valuation and earnings.
  • Percentage of Shares Shorted

    11.58% of the outstanding shares of 10x Genomics have been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 10x Genomics has recently increased by 1,022.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    10x Genomics does not currently pay a dividend.

  • Dividend Growth

    10x Genomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.58% of the outstanding shares of 10x Genomics have been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 10x Genomics has recently increased by 1,022.83%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    10x Genomics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for 10x Genomics this week, compared to 7 articles on an average week.
  • Search Interest

    9 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,238.00 in company stock.

  • Percentage Held by Insiders

    10.03% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 10x Genomics' insider trading history.
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Stock News Headlines

Short Interest in 10x Genomics (NASDAQ:TXG) Expands By 1,022.8%
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Headlines

TXG Stock Analysis - Frequently Asked Questions

10x Genomics' stock was trading at $14.36 at the beginning of 2025. Since then, TXG shares have decreased by 8.9% and is now trading at $13.08.

10x Genomics (NASDAQ:TXG) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.09. The firm's revenue was down 2.3% compared to the same quarter last year.
Read the conference call transcript
.

10x Genomics (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

10x Genomics' top institutional shareholders include ARK Investment Management LLC (11.28%), Sumitomo Mitsui Trust Group Inc. (4.89%), Assenagon Asset Management S.A. (1.39%) and IQ EQ FUND MANAGEMENT IRELAND Ltd (0.23%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo.
View institutional ownership trends
.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
8/03/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TXG
CIK
1770787
Fax
N/A
Employees
1,240
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$6.50
Potential Upside/Downside
+1.1%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$182.63 million
Net Margins
-25.14%
Pretax Margin
-24.56%
Return on Equity
-23.22%
Return on Assets
-18.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.37
Quick Ratio
4.68

Sales & Book Value

Annual Sales
$610.78 million
Price / Sales
2.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.81 per share
Price / Book
2.25

Miscellaneous

Outstanding Shares
123,130,000
Free Float
110,784,000
Market Cap
$1.61 billion
Optionable
Optionable
Beta
2.03

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:TXG) was last updated on 8/4/2025 by MarketBeat.com Staff
From Our Partners